CGEM

Cullinan Therapeutics, Inc.

Fundamental data last updated:October 4, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Pharmaceuticals

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

 


Analyze CGEM on TradingView

VALUATION

P/E

-4.11

Market Cap ($M USD)

$943.99M

Forward P/E

-9.41

PEG

-0.17

PRICE TO SALES

0.00

PRICE TO BOOK

2.48

EV / EBITDA

-3.71

5-Year Average P/E

Free Cash Flow Yield

-18.93%

DCF Value

$1.44

Graham Number

N/A

Price to FCF

-5.28

EV to FCF

-4.88

Earnings Yield

-24.31%

FCF Yield

-18.93%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$3.73

Next Year EPS Growth Estimate

-$1.63

Next Year Revenue Growth Estimate

$228.55M

Return on Equity (ROE)

-51.45%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.01

Piotroski F-Score

1

Altman Z-Score

11.98

Return on Invested Capital (ROIC)

-65.34%

Current Ratio

10.28

Quick Ratio

10.28

Net Debt to EBITDA

0.31

Interest Coverage

0.00

Gross Profit margin

0.00%

FCF PER SHARE

$-3.02

REVENUE PER SHARE

$0.00

Analyze CGEM on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to have misjudged Cullinan Therapeutics, Inc., with its snapshot price trading significantly above its DCF value. The Forward P/E and Earnings Yield are deep in negative territory, signaling a lack of profitability and potential overvaluation. Yet, the Altman Z-score of 11.40 suggests financial stability, indicating the company is not at immediate risk of distress. Despite a “Buy” consensus rating, the negative ROIC and earnings yield paint a picture of a company struggling to generate returns on its investments. This is a stock priced for perfection, yet its fundamentals tell a different story.

AI Exposure / Tech Reliance

In the rapidly evolving healthcare sector, Cullinan Therapeutics is positioned to leverage AI advancements in drug discovery and personalized medicine. The pharmaceutical industry is increasingly integrating AI to streamline R&D processes, potentially reducing costs and time to market. However, the company's current metrics suggest it may need to improve its execution to fully capitalize on these technological shifts.

The Bull Case

For the value-driven investor, Cullinan Therapeutics offers a compelling narrative of potential growth. The company's negligible debt and high current ratio highlight its strong liquidity position, providing a cushion for future investments. Despite a low Piotroski F-Score, the impressive Altman Z-score indicates robust financial health. The significant sales growth projection suggests the company could be on the cusp of a turnaround, making it an attractive option for those willing to bet on its future execution.

The Bear Case

Cullinan Therapeutics faces significant structural risks, with its negative EPS and FCF Yield underscoring a lack of profitability. The Price/Book ratio of 2.35 suggests the stock is not cheap, especially when coupled with a zero Price/Sales ratio, indicating no revenue generation. The company is technically overextended, trading close to its 52-week high, which could deter cautious investors. With no operating margin and a negative ROIC, the company must address its operational inefficiencies to justify its current valuation.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$31.00

Institutional Ownership %

1-Year Beta

-0.09

Insider Buying % (6 Mo)

Distance to 52-Week High

8.98%

Distance to 52-Week Low

63.02%

EARNINGS SURPRISE %

10.27%

50-DAY SMA

$14.30

200-DAY SMA

$10.93

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.